In the next five years, the Chinese medical science and technology innovation will do 8 things.
Recently, the state ministry of science and technology issued by the much starker choices-and graver consequences-in "scientific and technological innovation of Chinese medicine special planning, pointed out the direction of the scientific and technological innovation of Chinese medicine for the next five years, and this is our first about plans for the development of the science and technology innovation of Chinese medicine.
Sure! In the next five years, Chinese medicine science and technology innovation will roll up the sleeves for eight things:
(1) the key technologies and methods of innovation in development.
Deepen the inheritance and innovation of traditional Chinese medicine.
(3) to improve traditional Chinese medicine against major disease levels.
Develop the health service technology of traditional Chinese medicine.
Promote the protection and value of TCM resources.
(6) strengthening research and development of traditional Chinese medicine and product development.
(7) promote standardization and internationalization of traditional Chinese medicine.
Strengthen the inheritance and innovation of ethnic medicine.
▍ Chinese medicine industry policy is good
Since March 25, 2013, the state administration of traditional Chinese medicine issued the prevention of traditional Chinese medicine health care (not cure disease) service outline (2013-2020), "science and technology innovation, to the end of 2016 the law of the law of the People's Republic of China on Chinese medicine, Chinese medicine will be the support is upgraded to the height of the law, due to half moon on July 1, after the official start of the implementation.
According to the author preliminary incomplete statistics, in just two years the central ministries issued in succession of traditional Chinese medicine industry in our country more than 10 copies of the supporting policy of the development of the file, in the domestic few an industry supporting policy documents released density can match.
According to specific involving these support documents of traditional Chinese medicine industry value chain link, both the upper reaches of the medicinal plant protection link related planning and policy, also have a middle medicine circulation and trade link policy and opinion. The innovation in the value chain is involved in the 13th five-year plan for the innovation of traditional Chinese medicine.
▍ countries to further promote Chinese medicine varieties, these varieties best chance
In the national science and technology department's 13th five-year plan for the innovation of traditional Chinese medicine, there is a positive encouraging attitude about the great variety of traditional Chinese medicine and the internationalization of traditional Chinese medicine.
In terms of specific indicators, we will strive to produce 3 to 5 Chinese medicine health products with a value of 1 billion yuan in the 13th five-year plan period, 1 to 2 international brands.
The author according to who advocate "able to oral is not injected muscle injection intravenous not" principle, and the current Chinese medicine internationalization progress of the fastest 7 varieties have six varieties is the current situation of oral medications, filter listed company sales revenue exceeds 500 million oral proprietary Chinese medicine brand 20.
These brands in the future the most opportunity to become a business card, traditional Chinese medicine industry development in the future leader in products output value reached 1 billion yuan group, even become international famous brands of potential candidates.
(note: the data is derived from the annual reports of the listed companies, some of which are based on the sales figures, and the figures are sorted by the sales revenue; the data is for reference)
Oriental gum
The company's core products, the glue series, with ginseng, deer antler and the "nourishing the three treasures", is the traditional Chinese medicine that inherits more than 3000 years.
Gelatin is one of the earliest medical classic "cold-induced febride as a tonic, compendium of materia medica as blood effective medicine, the current e-jiao has become the single biggest OTC product, sales income over 5 billion yuan, the column of nourishing the first brand of preserve one's health. This kind of product is "much starker choices-and graver consequences-in" scientific and technological innovation of Chinese medicine special planning special offered to key mining from the classic Cuban side of preserve one's health, the type of nourishing health food, medicine edible medicinal materials as the source of food.
Gelatin company whole industrial chain, the whole process of tracing, perceived quality, dosage form, dictionaries, cultural experience marketing and value return to the three project, further established the company's industry leadership and brand positioning. Glue focus two platforms, implement the glue platform and the experience factory upgrade, the compound glue pulp turns to the gas and blood, and the development of guangpu health.
The product of the company product is a series of products, has the good foundation of forming the product group.
tasly
In the field of modern Chinese medicine, the company is constantly building an international major drug system. Compound danshen dropping pill the world's first complete American FDA Ⅲ global multicenter randomized, double-blind, large sample clinical trials of the modern Chinese native medicine preparation, the results of the study once again proved that the safety, efficacy and quality control of compound danshen dropping pill.
Formation of top level Analysis to summarize the clinical trial Report (Topline Analysis Report) ", according to the compound danshen dropping pill in the treatment of chronic stable angina has significant concentration-response relationship, test meet the FDA to compound Chinese medicine research and development need to disassemble the study drug administration management requirements, at the same time effective substances control range of clinical trial samples can be used as listed on the basis of product quality standards. It is of great significance to promote the modernization of traditional Chinese medicine and the strategy of international country.
The company is the pioneer of the internationalization of Chinese traditional Chinese medicine. Company varieties of compound danshen dropping pill as early as in 1996 was elected as the first compound proprietary Chinese medicine, according to the FDA to 2006 tasly second applied to the FDA for new IND, clear indications in the prevention and treatment of chronic stable angina, is currently China's fastest varieties of traditional Chinese medicine internationalization progress. Most chance of becoming the much starker choices-and graver consequences-in "scientific and technological innovation of Chinese medicine special planning, especially put forward to form of Chinese traditional medicine international famous brand one or two of the most competitive candidates.
▍ 1212 disease clinical pathway, to carry out the most potential variety of evidence-based medicine
Late last year and recently released 1212 kinds of clinical pathway, can enter the drug most development opportunities of clinical pathway, but has now released pharmaceutical basic clinical pathway for western medicine. The author thinks that the following will have more kinds of clinical pathway, a drug to enter the clinical pathway is the basic condition of clinical efficacy and safety of the drug, so varieties with promoting evidence-based medical research will be the best chance.
Promulgated by the state ministry of science and technology has much starker choices-and graver consequences-in "scientific and technological innovation of Chinese medicine special planning, strengthen the development of traditional Chinese medicine research and development technology and products requirements, strengthen the safety of traditional Chinese medicine research, set up in line with international standards for safety evaluation of new drugs of Chinese medicine, Chinese medicine big variety standard, etc., to strengthen the safety of clinical medication guide.
It is clear that the work of evidence-based medicine and safety reappraisal is important, and these varieties can be found in the future.
Such a list of 20 varieties have some varieties are ongoing or completed work of evidence-based medicine, for the future of product sales, as income as a member of more than 1 billion varieties of products, and even abroad has positive significance. In the future, the development of Chinese herbal products and the whole Chinese traditional Chinese medicine will depend on these varieties.
Based on the data, these types of evidence-based medicine are carried out as follows:
(note: the information is from the company's annual report.)
Step medicine
Despite the high cost of selling pharmaceutical products, it has to be noted that the company has a unique perspective on the development of its products.
Pharmaceutical company is given priority to with cardiovascular proprietary Chinese medicine, the company has successfully developed, to cultivate the heart failure capsule, metacentric particles and Dan red injection three famous exclusive varieties, the total sales revenue reached 9.006 billion yuan in 2016.
Among them, oral medications varieties heart failure capsule, metacentric particles is after a long market test maturity varieties, such as stroke, cardiac arrhythmia curative effect is a common disease of heart head blood-vessel, widely praised by the doctors and patients. In 2012, the stabilised particles completed a three-year clinical trial of evidence-based medicine, and its effect on arrhythmias was reconfirmed. The evidence-based medicine of the brain capsule is also steadily underway.
Heart failure capsule, metacentric particles also included in the catalog of national essential drugs and the 2017 version of the catalog of health care, enjoyment of national health insurance fund proportion of reimbursement policy support. As a major drug in the cardiovascular system, the market size of the brain will be further enhanced in the future. |
